Couples and Dyadic Psychedelic Therapy in Canada

Couples and dyadic psychedelic-assisted therapy is an emerging clinical model where one partner has PTSD and treatment involves both partners together in a structured conjoint protocol. One published pilot study exists: six couples, no control arm, and large within-group effect sizes that are hypothesis-generating evidence only, not proof of efficacy. This article explains what the model is, what the evidence actually shows, and what ATMA CENA currently offers.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334 on 2026-05-28.

Key takeaways

• Dyadic psychedelic-assisted therapy is investigational. There are no completed randomized controlled trials in any format.
• The only published pilot data is Monson et al. (2020): 6 couples, one partner with PTSD, no control arm, 2 MDMA sessions within a condensed CBCT protocol. Large within-group effect sizes (d up to 3.59) but no causal inference is possible. This is hypothesis-generating evidence.
• MDMA has a plausible mechanism for couples work (oxytocin release, reduced amygdala reactivity to social threat, prosocial subjective effects), but a plausible mechanism is not established efficacy.
• A history of intimate partner violence (IPV) is typically a contraindication for any conjoint psychedelic format. Individual IPV screening is a required step before dyadic consideration.
• In Canada, legal access to MDMA-assisted therapy requires Health Canada approval on a case-by-case basis, initiated by a physician, and is not guaranteed. A dyadic request is more complex than a single-patient one.
• ATMA CENA offers conventional couples therapy and CoCare coordination; co-administration dyadic MDMA-assisted therapy is not a routine clinical service.
• Insurance coverage for dyadic psychedelic-assisted therapy is essentially absent.

If you and your partner want to understand what the evidence does and does not say about couples psychedelic-assisted therapy, book a free 15-minute information call with ATMA CENA's clinical team.

What is dyadic psychedelic-assisted therapy?

Dyadic psychedelic-assisted therapy is a conjoint model where both partners participate in a structured treatment protocol that includes at least one psychedelic dosing session. Two formats exist in the published literature. In a co-administration format, both partners receive the substance simultaneously. In an asymmetric format, one partner, typically the one with the primary diagnosis, receives the substance while the other participates as a non-dosed conjoint support person. Both formats are investigational. Neither has a completed randomized controlled trial. The dyadic model is grounded in established conjoint psychotherapies, most centrally Cognitive-Behavioral Conjoint Therapy (CBCT) for PTSD [Monson and Fredman 2012], combined with the pharmacological properties of MDMA.

What the evidence actually shows: Monson et al. 2020

The only published pilot data for couples MDMA-assisted therapy is Monson et al. (2020) in European Journal of Psychotraumatology [PMID: 33408811].

What they studied: 6 couples in which one partner had DSM-5 PTSD confirmed by the Clinician-Administered PTSD Scale (CAPS-5). The other partner did not have current PTSD. The protocol condensed a 15-session CBCT program into 7 weeks and added 2 MDMA dosing sessions (75 mg first session, 100 mg second session, with an optional supplemental half-dose at 1.5 hours). The study was funded by MAPS and had no control arm.

What they found: All 6 couples completed the protocol. No serious adverse events occurred. Within-group effect sizes for PTSD outcomes were large: clinician-rated d = 1.88 to 2.25 at post-treatment and follow-up; patient-rated d = 2.72 to 3.59; partner-rated d = 1.85 to 2.72 [Monson et al. 2020].

What this does not show: An uncontrolled pilot of 6 couples produces no control group, no randomization, and no ability to isolate what caused the change. Was it the MDMA? The condensed CBCT structure? The therapeutic alliance? The passage of time? Expectancy effects? These effect sizes are within-group and cannot be attributed to the treatment. They are large enough to justify a controlled trial. They do not establish efficacy.

A follow-on study protocol was published in 2024 (PMC11237689) describing a planned brief CBCT-plus-MDMA pilot with a more rigorous design. That study had not published results as of the date of this article. Dyadic MDMA-assisted therapy remains at the hypothesis-generating stage.

Key stat: The Monson 2020 pilot included 6 couples and had no control arm. The within-group effect sizes (d up to 3.59) are hypothesis-generating: they support designing a controlled trial, not drawing efficacy conclusions.

Why MDMA in particular for couples?

Wagner, Mithoefer, and Monson (2019) laid out the proposed mechanism in Frontiers in Psychology [PMID: 31178802]. The rationale draws on three converging pharmacological observations:

• Oxytocin release with MDMA administration [Dumont et al. 2009, PMID: 19562632], with hypothesized effects on attachment-relevant social cognition
• Reduced amygdala reactivity to social threat cues, observed on neuroimaging and proposed to lower fear-based defensiveness during conjoint trauma processing
• Prosocial and empathogenic subjective effects, including increased perceived closeness, reduced defensiveness, and increased self-disclosure [Bedi, Hyman, de Wit 2010, PMID: 20947066]

These mechanisms are supported by basic and clinical research. They do not by themselves establish efficacy or safety of the dyadic protocol in any specific population. That requires controlled trial evidence, which does not yet exist for the dyadic format.

When dyadic psychedelic-assisted therapy may be clinically relevant

The published literature converges on a small number of situations where a dyadic approach has been proposed or studied:

• PTSD where the partner has been substantially affected: secondary traumatic stress, accommodation behaviours, relationship distress. This is the population Monson et al. (2020) studied.
• Caregiver-patient pairs in serious illness: end-of-life distress where existential burden is shared and relational. Wagner and colleagues have published conceptual work on this format.
• Relationship distress with mood disorder where standard couples therapy has not been sufficient: proposed as a clinical rationale, not studied in controlled trials.

These are situations where the relational system itself is a meaningful target of treatment. Dyadic consideration is not appropriate simply because one partner is in a relationship.

IPV screening, consent, and power dynamics

The dyadic format introduces clinical risks that do not exist in individual psychedelic-assisted therapy.

Intimate partner violence (IPV) screening is required. A history of IPV is typically a contraindication for any conjoint psychedelic format. Conjoint settings can endanger a victim of IPV by exposing them in a vulnerable altered state, can be used coercively by perpetrators, and can compromise the safety required for honest disclosure. IPV screening instruments, including the Composite Abuse Scale (CAS) [Hegarty et al. 1999], the HITS screen [Sherin et al. 1998, PMID: 9669164], and the Woman Abuse Screening Tool (WAST), should be administered individually to each partner, in separate sessions, with explicit confidentiality protections. This is a standard requirement in the CBCT for PTSD framework and in the Wagner/Monson protocols.

Power dynamics and consent. Even without IPV, asymmetries of financial power, immigration status, caregiving dependency, or neurocognitive status affect the validity of consent in a conjoint protocol. Each partner must consent individually to the protocol, to the substance, to the conjoint format, and to the specific confidentiality framework. Material disclosed or expressed under MDMA, including emotionally intimate interactions, must be consented to in advance. The ethics literature on psychedelic-assisted therapy addresses this question explicitly, and the dyadic format raises it further.

Confidentiality. Dyadic therapy structurally alters confidentiality. A "no-secrets" versus "limited-secrets" policy must be defined and consented to before the first session. What happens to material that emerges under MDMA in the dosing session must be addressed explicitly.

How Health Canada access works for a dyadic request

MDMA and psilocybin are restricted drugs under Canada's Controlled Drugs and Substances Act. Legal patient access to MDMA-assisted therapy requires Health Canada approval on a case-by-case basis, initiated by a physician, and is not guaranteed. This pathway is primarily used for adults with PTSD [Health Canada notice].

A dyadic request adds complexity beyond a single-patient one:

• Two separate patient-specific applications are required, one for each partner who will receive the substance
• Both partners must independently meet the eligibility criteria; approval is granted for an individual patient, not for a relationship unit
• The clinical justification must address each patient's individual indication and the rationale for the conjoint format
• Reviewer expectations for an emerging investigational format are higher; the supporting evidence base (Monson 2020 and related conceptual work) is limited

In practice, dyadic requests for MDMA in PTSD-affected couples are rare in Canada and would typically be advanced only by clinicians with specific training in both psychedelic-assisted therapy and conjoint trauma therapy.

What ATMA CENA currently offers for couples

What ATMA CENA does offer today:

• Conventional couples therapy as part of its psychotherapy services
• Involvement of a partner in preparation and integration sessions for an individual's ketamine, Spravato, or physician-initiated psilocybin course. This is a one-dosed asymmetric format in which the partner is not dosed but participates in the therapeutic frame
• CoCare: if you already work with a therapist who has the appropriate training, ATMA CENA can partner with them by building a service agreement. See CoCare
• Comprehensive couples assessment including individual IPV screening, power-dynamic assessment, and confidentiality structuring where any conjoint involvement is being considered

Co-administration dyadic MDMA-assisted therapy is not currently a routine ATMA CENA clinical service. If you are asking whether it could be pursued through Health Canada's case-by-case pathway for your specific situation, book a free information call, and ATMA CENA's clinical team can give you an honest assessment.

Frequently asked questions

What is dyadic psychedelic-assisted therapy?

Dyadic psychedelic-assisted therapy is a conjoint clinical model where both partners participate in a structured treatment protocol that includes psychedelic-assisted dosing sessions. The most-studied format involves one partner with PTSD receiving MDMA within a condensed Cognitive-Behavioral Conjoint Therapy (CBCT) protocol. It is investigational, with no completed randomized controlled trials for any dyadic psychedelic format.

What does the research actually show for couples MDMA therapy?

The only published pilot data is Monson et al. (2020): 6 couples, one partner with PTSD, 2 MDMA dosing sessions within a 7-week condensed CBCT protocol, no control arm. Within-group effect sizes were large (d up to 3.59 on patient-rated PTSD measures). Because there was no control arm, it is not possible to draw conclusions about what caused the improvement. This is hypothesis-generating evidence that supports designing a controlled trial.

Is dyadic psychedelic-assisted therapy approved in Canada?

No. It is investigational. Legal access to MDMA in Canada requires Health Canada approval on a case-by-case basis, initiated by a physician. A dyadic request requires two separate patient applications, independent clinical justification for each partner, and a rationale for the conjoint format. Approval is not guaranteed.

Why is MDMA the focus for couples therapy rather than psilocybin or ketamine?

MDMA produces oxytocin release, reduces amygdala reactivity to social threat cues, and creates prosocial and empathogenic subjective effects that make it plausible for conjoint trauma work. These mechanisms were described by Wagner, Mithoefer, and Monson (2019). Psilocybin and ketamine have been studied far less in dyadic formats; no significant dyadic pilot data exists for either in a couples context.

Is intimate partner violence a contraindication for dyadic therapy?

Yes, typically. A history of IPV is generally a contraindication for any conjoint psychedelic-assisted therapy format. Conjoint settings can endanger a victim of IPV and compromise the safety required for honest disclosure. Individual IPV screening with each partner separately is a required step before any dyadic consideration.

Can both partners receive MDMA at the same time?

That is the co-administration format studied in the Monson (2020) pilot. It is investigational. The asymmetric format, one partner dosed and one participating as a non-dosed conjoint support, is a distinct structural variant. Both are investigational; neither is approved.

What if my partner's condition is not PTSD?

The published dyadic evidence base is focused on PTSD (Monson 2020) and cancer caregiver-patient distress (conceptual work by Wagner and colleagues). There is no significant dyadic pilot evidence for other conditions. Dyadic consideration for other presentations would be even more speculative than the already-limited PTSD evidence base.

Is couples psychedelic therapy covered by insurance?

Essentially no. Conventional couples therapy may be covered under extended health benefits as standard psychotherapy. The psychedelic substance and its administration through Health Canada's case-by-case pathway are not covered. A dyadic request is more complex, and there is no insurer prior-authorization pathway for a dyadic MDMA-assisted therapy protocol in Canada.

What does ATMA CENA offer for couples right now?

ATMA CENA offers conventional couples therapy, partner involvement in preparation and integration for an individual's substance-assisted therapy course, and CoCare coordination with an existing, appropriately trained therapist. Co-administration dyadic MDMA-assisted therapy is not a routine clinical service. The honest answer about what is and is not available for your situation comes from the information call.

My partner has bipolar disorder. Can we do dyadic therapy?

Bipolar disorder in either partner is a meaningful clinical consideration. Psychedelic-assisted therapy in bipolar populations is restricted to specific evidence-supported pathways (off-label ketamine with mood-stabilizer coverage). Bipolar disorder and psychedelic-assisted therapy carries its own full framing, and any conjoint involvement would follow the same individual safeguards.

Compliance disclaimer

Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act. Legal patient access to psilocybin- or MDMA-assisted therapy requires Health Canada approval on a case-by-case basis, initiated by a physician, and is not guaranteed. This pathway is primarily used for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness (psilocybin) and for adults with PTSD (MDMA). Dyadic MDMA-assisted therapy is investigational; no dyadic psychedelic protocol is approved for any indication in Canada. Nothing in this article should be construed as a clinical recommendation for a specific individual. Clinical decisions belong with a qualified prescribing physician and regulated psychotherapy provider.

Health Canada notice on psychedelic-assisted psychotherapy requests

About the author

Reverdi Darda, RN, BScN, Reg #61707 | CEO & Founder, ATMA CENA

Reverdi Darda, RN is CEO & Founder of ATMA CENA and a Registered Nurse with over three decades of experience in healthcare operations, community engagement, policy development, and strategic planning. A recognized leader in mental health access, Reverdi has dedicated her career to advancing evidence-based treatment models and advocating for policy change that prioritizes effective care. She founded ATMA CENA to expand practitioner and public access to psychedelic-assisted therapy across Canada.

Sources

1. Monson CM, Wagner AC, Mithoefer AT, Liebman RE, Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Doblin R, Mithoefer MC. (2020). MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial. Eur J Psychotraumatol, 11(1):1840123. PMID: 33408811. https://pubmed.ncbi.nlm.nih.gov/33408811/
2. Wagner AC, Mithoefer MC, Mithoefer AT, Monson CM. (2019). Couple Therapy With MDMA: Proposed Pathways of Action. Front Psychol, 10:1136. PMID: 31178802. https://pubmed.ncbi.nlm.nih.gov/31178802/
3. Monson CM, Fredman SJ. (2012). Cognitive-Behavioral Conjoint Therapy for PTSD: Harnessing the Healing Power of Relationships. Guilford Press.
4. Dumont GJ, Sweep FC, van der Steen R, et al. (2009). Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (MDMA) administration. Soc Neurosci, 4(4):359-66. PMID: 19562632. https://pubmed.ncbi.nlm.nih.gov/19562632/
5. Bedi G, Hyman D, de Wit H. (2010). Is ecstasy an "empathogen"? Effects of MDMA on prosocial feelings and identification of emotional states in others. Biol Psychiatry, 68(12):1134-40. PMID: 20947066. https://pubmed.ncbi.nlm.nih.gov/20947066/
6. Sherin KM, Sinacore JM, Li XQ, Zitter RE, Shakil A. (1998). HITS: a short domestic violence screening tool for use in a family practice setting. Fam Med, 30(7):508-12. PMID: 9669164. https://pubmed.ncbi.nlm.nih.gov/9669164/
7. Hegarty K, Sheehan M, Schonfeld C. (1999). A multidimensional definition of partner abuse: development and preliminary validation of the Composite Abuse Scale (CAS). J Fam Violence, 14:399-415.
8. Health Canada (2022). Notice to stakeholders: requests involving psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html

Related articles

• Who We Serve: Populations Hub (parent hub)
• MDMA-Assisted Therapy in Canada (Hub)
• PTSD and Psychedelic-Assisted Therapy
• CoCare: How ATMA CENA Works With Your Existing Therapist

---

Last updated: 2026-05-28. This article is reviewed every 6 months or when new dyadic psychedelic-assisted therapy evidence is published.